Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 90


Management of Advanced Kidney Cancer: Kidney Cancer Research Network of Canada (KCRNC) consensus update 2019.

Hotte SJ, Kapoor A, Basappa NS, Bjarnason G, Canil C, Conter HJ, Czaykowski P, Graham J, Gray S, Heng DYC, Karakiewicz PI, Kollmannsberger C, Lalani AA, North SA, Patenaude F, Soulières D, Violette P, Winquist E, Wood LA, Dudani S, Maloni R, Reaume MN; Kidney Cancer Research Network of Canada.

Can Urol Assoc J. 2019 Oct;13(10):343-354. doi: 10.5489/cuaj.6256. No abstract available.


A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration-resistant Prostate Cancer: Canadian Cancer Trials Group Study IND205.

Hotte SJ, Chi KN, Joshua AM, Tu D, Macfarlane RJ, Gregg RW, Ruether JD, Basappa NS, Finch D, Salim M, Winquist EW, Torri V, North S, Kollmannsberger C, Ellard SL, Eigl BJ, Tinker A, Allan AL, Beja K, Annala M, Powers J, Wyatt AW, Seymour L; Canadian Cancer Trials Group (formerly NCIC Clinical Trials Group).

Clin Genitourin Cancer. 2019 Jun;17(3):201-208.e1. doi: 10.1016/j.clgc.2019.03.005. Epub 2019 Mar 15.


Management algorithms for metastatic prostate cancer.

Malone S, Shayegan B, Basappa NS, Chi K, Conter HJ, Hamilton RJ, Hotte SJ, Saad F, So A, Park-Wyllie L, Hew H, McLeod D, Gotto G.

Can Urol Assoc J. 2019 Apr 26. doi: 10.5489/cuaj.5840. [Epub ahead of print] Review.


Cost-effectiveness of docetaxel in high-volume hormone-sensitive metastatic prostate cancer.

Beca J, Majeed H, Chan KKW, Hotte SJ, Loblaw A, Hoch JS.

Can Urol Assoc J. 2019 Apr 26. doi: 10.5489/cuaj.5889. [Epub ahead of print]


Reversible Cabozantinib-Induced Cardiomyopathy.

Alhussein M, Hotte SJ, Leong DP.

Can J Cardiol. 2019 Apr;35(4):544.e1-544.e2. doi: 10.1016/j.cjca.2018.12.025. Epub 2018 Dec 29.


Phase I Study of BI 853520, an Inhibitor of Focal Adhesion Kinase, in Patients with Advanced or Metastatic Nonhematologic Malignancies.

de Jonge MJA, Steeghs N, Lolkema MP, Hotte SJ, Hirte HW, van der Biessen DAJ, Abdul Razak AR, De Vos FYFL, Verheijen RB, Schnell D, Pronk LC, Jansen M, Siu LL.

Target Oncol. 2019 Feb;14(1):43-55. doi: 10.1007/s11523-018-00617-1.


Randomized, Open-Label, Crossover Studies Evaluating the Effect of Food and Liquid Formulation on the Pharmacokinetics of the Novel Focal Adhesion Kinase (FAK) Inhibitor BI 853520.

Verheijen RB, van der Biessen DAJ, Hotte SJ, Siu LL, Spreafico A, de Jonge MJA, Pronk LC, De Vos FYFL, Schnell D, Hirte HW, Steeghs N, Lolkema MP.

Target Oncol. 2019 Feb;14(1):67-74. doi: 10.1007/s11523-018-00618-0.


The efficacy and safety of sunitinib given on an individualised schedule as first-line therapy for metastatic renal cell carcinoma: A phase 2 clinical trial.

Bjarnason GA, Knox JJ, Kollmannsberger CK, Soulieres D, Ernst DS, Zalewski P, Canil CM, Winquist E, Hotte SJ, North SA, Heng DYC, Macfarlane RJ, Venner PM, Kapoor A, Hansen AR, Eigl BJ, Czaykowski P, Boyd B, Wang L, Basappa NS.

Eur J Cancer. 2019 Feb;108:69-77. doi: 10.1016/j.ejca.2018.12.006. Epub 2019 Jan 14.


Exogenous estrogen therapy, testicular cancer, and the male to female transgender population: a case report.

Chandhoke G, Shayegan B, Hotte SJ.

J Med Case Rep. 2018 Dec 19;12(1):373. doi: 10.1186/s13256-018-1894-6.


Kidney Cancer Research Network of Canada consensus statement on the role of adjuvant therapy after nephrectomy for high-risk, non-metastatic renal cell carcinoma: A comprehensive analysis of the literature and meta-analysis of randomized controlled trials.

Karakiewicz PI, Zaffuto E, Kapoor A, Basappa NS, Bjarnason GA, Blais N, Breau RH, Canil C, Drachenberg D, Hotte SJ, Jeldres C, Jewett MAS, Kassouf W, Kollmannsberger C, Lavallée LT, Maloni R, Patenaude F, Pouliot F, Reaume MN, Sabbagh R, Shayegan B, So A, Soulières D, Tanguay S, Wood L, Bandini M.

Can Urol Assoc J. 2018 Jun;12(6):173-180. doi: 10.5489/cuaj.5187.


Disparity in public funding of therapies for metastatic castrate-resistant prostate cancer across Canadian provinces.

Woon DTS, Chandrasekar T, Aaron L, Basappa NS, Chi KN, Conter HJ, Gotto G, Hotte SJ, Malone S, Saad F, Shayegan B, Park-Wyllie L, Hamilton RJ.

Can Urol Assoc J. 2018 Oct;12(10):328-336. doi: 10.5489/cuaj.5378. Epub 2018 Jul 16.


Optimizing Anticancer Therapy in Metastatic Non-Castrate Prostate Cancer: American Society of Clinical Oncology Clinical Practice Guideline.

Morris MJ, Rumble RB, Basch E, Hotte SJ, Loblaw A, Rathkopf D, Celano P, Bangs R, Milowsky MI.

J Clin Oncol. 2018 May 20;36(15):1521-1539. doi: 10.1200/JCO.2018.78.0619. Epub 2018 Apr 2.


A randomized phase II study of pelareorep and docetaxel or docetaxel alone in men with metastatic castration resistant prostate cancer: CCTG study IND 209.

Eigl BJ, Chi K, Tu D, Hotte SJ, Winquist E, Booth CM, Canil C, Potvin K, Gregg R, North S, Zulfiqar M, Ellard S, Ruether JD, Le L, Kakumanu AS, Salim M, Allan AL, Feilotter H, Theis A, Seymour L.

Oncotarget. 2018 Jan 17;9(8):8155-8164. doi: 10.18632/oncotarget.24263. eCollection 2018 Jan 30.


Management of advanced kidney cancer: Canadian Kidney Cancer Forum (CKCF) consensus update 2017.

Reaume MN, Basappa NS, Wood L, Kapoor A, Bjarnason GA, Blais N, Breau RH, Canil C, Cheung P, Conter HJ, Hotte SJ, Jeldres C, Jewett MAS, Karakiewicz PI, Kollmannsberger C, Patenaude F, So A, Soulières D, Venner P, Violette P, Zalewski P, Chappell H, North SA; Kidney Cancer Research Network of Canada.

Can Urol Assoc J. 2017 Oct;11(10):310-320. doi: 10.5489/cuaj.4769. No abstract available.


A randomized phase 2 study of a HSP27 targeting antisense, apatorsen with prednisone versus prednisone alone, in patients with metastatic castration resistant prostate cancer.

Yu EY, Ellard SL, Hotte SJ, Gingerich JR, Joshua AM, Gleave ME, Chi KN.

Invest New Drugs. 2018 Apr;36(2):278-287. doi: 10.1007/s10637-017-0553-x. Epub 2017 Dec 18.


Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, phase 3 trial.

Beer TM, Hotte SJ, Saad F, Alekseev B, Matveev V, Fléchon A, Gravis G, Joly F, Chi KN, Malik Z, Blumenstein B, Stewart PS, Jacobs CA, Fizazi K.

Lancet Oncol. 2017 Nov;18(11):1532-1542. doi: 10.1016/S1470-2045(17)30605-8. Epub 2017 Oct 9.


Bone Health and Bone-Targeted Therapies for Nonmetastatic Prostate Cancer: A Systematic Review and Meta-analysis.

Alibhai SMH, Zukotynski K, Walker-Dilks C, Emmenegger U, Finelli A, Morgan SC, Hotte SJ, Tomlinson GA, Winquist E.

Ann Intern Med. 2017 Sep 5;167(5):341-350. doi: 10.7326/M16-2577. Epub 2017 Aug 8. Review.


First-line sunitinib or pazopanib in metastatic renal cell carcinoma: The Canadian experience.

Lalani AA, Li H, Heng DYC, Wood L, Kalirai A, Bjarnason GA, Sim HW, Kollmannsberger CK, Kapoor A, Hotte SJ, Vanhuyse M, Czaykowski P, Reaume MN, Soulieres D, Venner P, North S, Basappa NS.

Can Urol Assoc J. 2017 Mar-Apr;11(3-4):112-117. doi: 10.5489/cuaj.4398.


Bone Health and Bone-targeted Therapies for Prostate Cancer: a Programme in Evidence-based Care - Cancer Care Ontario Clinical Practice Guideline.

Alibhai SMH, Zukotynski K, Walker-Dilks C, Emmenegger U, Finelli A, Morgan SC, Hotte SJ, Winquist E; Cancer Care Ontario Genitourinary Cancer Disease Site Group.

Clin Oncol (R Coll Radiol). 2017 Jun;29(6):348-355. doi: 10.1016/j.clon.2017.01.007. Epub 2017 Feb 4. Review.


Androgen receptor axis-targeted agents.

Kapoor A, Hotte SJ.

Can Urol Assoc J. 2016 Aug;10(7-8Suppl3):S146-S148. Review. No abstract available.



Kapoor A, Hotte SJ.

Can Urol Assoc J. 2016 Aug;10(7-8Suppl3):S144-S145. Review. No abstract available. Erratum in: Can Urol Assoc J. 2016 Sep-Oct;10(9-10):E327.


Chemotherapy research for metastatic prostate cancer.

Kapoor A, Hotte SJ.

Can Urol Assoc J. 2016 Aug;10(7-8Suppl3):S140-S143. Review. No abstract available.


Localized prostate cancer.

Kapoor A, Hotte SJ.

Can Urol Assoc J. 2016 Aug;10(7-8Suppl3):S138-S139. Review. No abstract available.


Addressing taxane resistance in metastatic castration-resistant prostate cancer: a focus on chaperone proteins.

Hotte SJ.

Future Oncol. 2017 Feb;13(4):369-379. doi: 10.2217/fon-2016-0279. Epub 2016 Oct 7. Review.


Cytokines and cell adhesion molecules exhibit distinct profiles in health, ovarian cancer, and breast cancer.

Henderson MP, Hirte H, Hotte SJ, Kavsak PA.

Heliyon. 2016 Jan 22;2(1):e00059. doi: 10.1016/j.heliyon.2015.e00059. eCollection 2016 Jan.


A phase I dose-escalation study of apatorsen (OGX-427), an antisense inhibitor targeting heat shock protein 27 (Hsp27), in patients with castration-resistant prostate cancer and other advanced cancers.

Chi KN, Yu EY, Jacobs C, Bazov J, Kollmannsberger C, Higano CS, Mukherjee SD, Gleave ME, Stewart PS, Hotte SJ.

Ann Oncol. 2016 Jun;27(6):1116-22. doi: 10.1093/annonc/mdw068. Epub 2016 Feb 18.


A phase I trial of ANG1/2-Tie2 inhibitor trebaninib (AMG386) and temsirolimus in advanced solid tumors (PJC008/NCI♯9041).

Chiu JW, Hotte SJ, Kollmannsberger CK, Renouf DJ, Cescon DW, Hedley D, Chow S, Moscow J, Chen Z, Perry M, Diaz-Padilla I, Tan D, Hirte H, McWhirter E, Chen H, Siu LL, Bedard PL.

Invest New Drugs. 2016 Feb;34(1):104-11. doi: 10.1007/s10637-015-0313-8. Epub 2015 Dec 19.


Treatment of mCRPC in the AR-axis-targeted therapy-resistant state.

Chi K, Hotte SJ, Joshua AM, North S, Wyatt AW, Collins LL, Saad F.

Ann Oncol. 2015 Oct;26(10):2044-56. doi: 10.1093/annonc/mdv267. Epub 2015 Jun 22. Review.


The 2015 CUA-CUOG Guidelines for the management of castration-resistant prostate cancer (CRPC).

Saad F, Chi KN, Finelli A, Hotte SJ, Izawa J, Kapoor A, Kassouf W, Loblaw A, North S, Rendon R, So A, Usmani N, Vigneault E, Fleshner NE.

Can Urol Assoc J. 2015 Mar-Apr;9(3-4):90-6. doi: 10.5489/cuaj.2526.


Chemoradiotherapy with or without panitumumab in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-1): a randomised, controlled, open-label phase 2 trial.

Mesía R, Henke M, Fortin A, Minn H, Yunes Ancona AC, Cmelak A, Markowitz AB, Hotte SJ, Singh S, Chan AT, Merlano MC, Skladowski K, Zhang A, Oliner KS, VanderWalde A, Giralt J.

Lancet Oncol. 2015 Feb;16(2):208-20. doi: 10.1016/S1470-2045(14)71198-2. Epub 2015 Jan 15.


Evaluation of second-line and subsequent targeted therapies in metastatic renal cell cancer (mRCC) patients treated with first-line cediranib.

Richter S, Seah JA, Pond GR, Gan HK, Mackenzie MJ, Hotte SJ, Mukherjee SD, Murray N, Kollmannsberger C, Heng D, Haider MA, Halford R, Ivy SP, Moore MJ, Sridhar SS.

Can Urol Assoc J. 2014 Nov;8(11-12):398-402. doi: 10.5489/cuaj.2426.


Abiraterone acetate for patients with metastatic castration-resistant prostate cancer progressing after chemotherapy: final analysis of a multicentre, open-label, early-access protocol trial.

Sternberg CN, Castellano D, Daugaard G, Géczi L, Hotte SJ, Mainwaring PN, Saad F, Souza C, Tay MH, Garrido JM, Galli L, Londhe A, De Porre P, Goon B, Lee E, McGowan T, Naini V, Todd MB, Molina A, George DJ; Abiraterone Global EAP Investigators.

Lancet Oncol. 2014 Oct;15(11):1263-8. doi: 10.1016/S1470-2045(14)70417-6. Epub 2014 Sep 18. Erratum in: Lancet Oncol. 2014 Nov;15(12):e528.


A phase I, dose-escalation trial of continuous- and pulsed-dose afatinib combined with pemetrexed in patients with advanced solid tumors.

Chu QS, Sangha R, Hotte SJ, Sergenson G, Schnell D, Chand VK, Hirte HW.

Invest New Drugs. 2014 Dec;32(6):1226-35. doi: 10.1007/s10637-014-0139-9. Epub 2014 Jul 19.


Thromboembolic events in patients with urothelial carcinoma undergoing neoadjuvant chemotherapy and radical cystectomy.

Zareba P, Patterson L, Pandya R, Margel D, Hotte SJ, Mukherjee SD, Elavathil L, Daya D, Shayegan B, Pinthus JH.

Urol Oncol. 2014 Oct;32(7):975-80. doi: 10.1016/j.urolonc.2014.03.025. Epub 2014 Jul 11.


A randomized phase II study of cediranib alone versus cediranib in combination with dasatinib in docetaxel resistant, castration resistant prostate cancer patients.

Spreafico A, Chi KN, Sridhar SS, Smith DC, Carducci MA, Kavsak P, Wong TS, Wang L, Ivy SP, Mukherjee SD, Kollmannsberger CK, Sukhai MA, Takebe N, Kamel-Reid S, Siu LL, Hotte SJ.

Invest New Drugs. 2014 Oct;32(5):1005-16. doi: 10.1007/s10637-014-0106-5. Epub 2014 May 3.


Assessing the necessity of including a crossover period with dual reporting when changing total prostate-specific antigen methods.

Rutledge AC, Pond GR, Hotte SJ, Kavsak PA.

Clin Biochem. 2014 Jul;47(10-11):897-900. doi: 10.1016/j.clinbiochem.2014.03.027. Epub 2014 Apr 12.


A randomized phase II efficacy and safety study of vandetanib (ZD6474) in combination with bicalutamide versus bicalutamide alone in patients with chemotherapy naïve castration-resistant prostate cancer.

Azad AA, Beardsley EK, Hotte SJ, Ellard SL, Klotz L, Chin J, Kollmannsberger C, Mukherjee SD, Chi KN.

Invest New Drugs. 2014 Aug;32(4):746-52. doi: 10.1007/s10637-014-0091-8. Epub 2014 Mar 28.


A phase I study of the combination of ro4929097 and cediranib in patients with advanced solid tumours (PJC-004/NCI 8503).

Sahebjam S, Bedard PL, Castonguay V, Chen Z, Reedijk M, Liu G, Cohen B, Zhang WJ, Clarke B, Zhang T, Kamel-Reid S, Chen H, Ivy SP, Razak AR, Oza AM, Chen EX, Hirte HW, McGarrity A, Wang L, Siu LL, Hotte SJ.

Br J Cancer. 2013 Aug 20;109(4):943-9. doi: 10.1038/bjc.2013.380. Epub 2013 Jul 18.


A phase Ib combination study of RO4929097, a gamma-secretase inhibitor, and temsirolimus in patients with advanced solid tumors.

Diaz-Padilla I, Hirte H, Oza AM, Clarke BA, Cohen B, Reedjik M, Zhang T, Kamel-Reid S, Ivy SP, Hotte SJ, Razak AA, Chen EX, Brana I, Wizemann M, Wang L, Siu LL, Bedard PL.

Invest New Drugs. 2013 Oct;31(5):1182-91. doi: 10.1007/s10637-013-0001-5. Epub 2013 Jul 17.


A phase I study of the oral gamma secretase inhibitor R04929097 in combination with gemcitabine in patients with advanced solid tumors (PHL-078/CTEP 8575).

Richter S, Bedard PL, Chen EX, Clarke BA, Tran B, Hotte SJ, Stathis A, Hirte HW, Razak AR, Reedijk M, Chen Z, Cohen B, Zhang WJ, Wang L, Ivy SP, Moore MJ, Oza AM, Siu LL, McWhirter E.

Invest New Drugs. 2014 Apr;32(2):243-9. doi: 10.1007/s10637-013-9965-4. Epub 2013 May 5.


Systemic therapy in men with metastatic castration-resistant prostate cancer: a systematic review.

Loblaw DA, Walker-Dilks C, Winquist E, Hotte SJ; Genitourinary Cancer Disease Site Group of Cancer Care Ontario's Program in Evidence-Based Care.

Clin Oncol (R Coll Radiol). 2013 Jul;25(7):406-30. doi: 10.1016/j.clon.2013.03.002. Epub 2013 Apr 12. Review.


A phase II study of cediranib (AZD 2171) in treatment naive patients with progressive unresectable recurrent or metastatic renal cell carcinoma. A trial of the PMH phase 2 consortium.

Sridhar SS, Mackenzie MJ, Hotte SJ, Mukherjee SD, Tannock IF, Murray N, Kollmannsberger C, Haider MA, Chen EX, Halford R, Wang L, Ivy SP, Moore MJ.

Invest New Drugs. 2013 Aug;31(4):1008-15. doi: 10.1007/s10637-013-9931-1. Epub 2013 Jan 26.


A phase II trial of dacomitinib, an oral pan-human EGF receptor (HER) inhibitor, as first-line treatment in recurrent and/or metastatic squamous-cell carcinoma of the head and neck.

Abdul Razak AR, Soulières D, Laurie SA, Hotte SJ, Singh S, Winquist E, Chia S, Le Tourneau C, Nguyen-Tan PF, Chen EX, Chan KK, Wang T, Giri N, Mormont C, Quinn S, Siu LL.

Ann Oncol. 2013 Mar;24(3):761-9. doi: 10.1093/annonc/mds503. Epub 2012 Oct 28.


Feasibility of real time next generation sequencing of cancer genes linked to drug response: results from a clinical trial.

Tran B, Brown AM, Bedard PL, Winquist E, Goss GD, Hotte SJ, Welch SA, Hirte HW, Zhang T, Stein LD, Ferretti V, Watt S, Jiao W, Ng K, Ghai S, Shaw P, Petrocelli T, Hudson TJ, Neel BG, Onetto N, Siu LL, McPherson JD, Kamel-Reid S, Dancey JE.

Int J Cancer. 2013 Apr 1;132(7):1547-55. doi: 10.1002/ijc.27817. Epub 2012 Oct 11.


A phase II study of sunitinib in recurrent and/or metastatic adenoid cystic carcinoma (ACC) of the salivary glands: current progress and challenges in evaluating molecularly targeted agents in ACC.

Chau NG, Hotte SJ, Chen EX, Chin SF, Turner S, Wang L, Siu LL.

Ann Oncol. 2012 Jun;23(6):1562-70. doi: 10.1093/annonc/mdr522. Epub 2011 Nov 11.


Progression-free survival as a clinical trial endpoint in advanced renal cell carcinoma.

Hotte SJ, Bjarnason GA, Heng DY, Jewett MA, Kapoor A, Kollmannsberger C, Maroun J, Mayhew LA, North S, Reaume MN, Ruether JD, Soulieres D, Venner PM, Winquist EW, Wood L, Yong JH, Saad F.

Curr Oncol. 2011 Oct;18 Suppl 2:S11-9.


Prophylactic feeding tubes for patients with locally advanced head-and-neck cancer undergoing combined chemotherapy and radiotherapy-systematic review and recommendations for clinical practice.

Orphanidou C, Biggs K, Johnston ME, Wright JR, Bowman A, Hotte SJ, Esau A, Myers C, Blunt V, Lafleur M, Sheehan B, Griffin MA.

Curr Oncol. 2011 Aug;18(4):e191-201.


Cardiac troponin testing in the acute care setting: ordering, reporting, and high sensitivity assays--an update from the Canadian society of clinical chemists (CSCC).

Kavsak PA, Allen LC, Apple FS, Booth RA, Chan PC, Delvin E, Fraser A, Fu L, Gornall D, Collier C, Hill S, Hoffman B, Huang Y, Lavoie J, Lou A, Mattman A, McQueen M, Meng QH, Oleschuk C, Pudek M, Randell E, Sohn KY, Thorlacius L, Yip PM, Dahdah N, Devereaux PJ, Dhesy-Thind S, Hotte SJ, Worster A.

Clin Biochem. 2011 Nov;44(16):1273-7. doi: 10.1016/j.clinbiochem.2011.08.001. Epub 2011 Aug 7. No abstract available.


A phase II study of sorafenib in combination with bicalutamide in patients with chemotherapy-naive castration resistant prostate cancer.

Beardsley EK, Hotte SJ, North S, Ellard SL, Winquist E, Kollmannsberger C, Mukherjee SD, Chi KN.

Invest New Drugs. 2012 Aug;30(4):1652-9. doi: 10.1007/s10637-011-9722-5. Epub 2011 Jul 23.


A phase 2 study of patupilone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel: Canadian Urologic Oncology Group study P07a.

Chi KN, Beardsley E, Eigl BJ, Venner P, Hotte SJ, Winquist E, Ko YJ, Sridhar SS, Weber D, Saad F.

Ann Oncol. 2012 Jan;23(1):53-8. doi: 10.1093/annonc/mdr336. Epub 2011 Jul 16.


Supplemental Content

Loading ...
Support Center